PURPOSE: To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. PATIENTS AND METHODS: One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. RESULTS: Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse-free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low beta 2-microglobulin level (< 4 g/L) also tended to have a favorable prognostic impact. The most important post-transplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. CONCLUSION: Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.
PURPOSE: To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma. PATIENTS AND METHODS: One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission. RESULTS: Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse-free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low beta 2-microglobulin level (< 4 g/L) also tended to have a favorable prognostic impact. The most important post-transplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival. CONCLUSION:Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.
Authors: Alexandra Gomez-Arteaga; Gunjan L Shah; Raymond E Baser; Michael Scordo; Josel D Ruiz; Adam Bryant; Parastoo B Dahi; Arnab Ghosh; Oscar B Lahoud; Heather J Landau; Ola Landgren; Brian C Shaffer; Eric L Smith; Guenther Koehne; Miguel-Angel Perales; Sergio A Giralt; David J Chung Journal: Biol Blood Marrow Transplant Date: 2020-07-23 Impact factor: 5.742
Authors: Sarah A Holstein; Vera J Suman; Kouros Owzar; Katelyn Santo; Don M Benson; Thomas C Shea; Thomas Martin; Margarida Silverman; Luis Isola; Ravi Vij; Bruce D Cheson; Charles Linker; Kenneth C Anderson; Paul G Richardson; Philip L McCarthy Journal: Biol Blood Marrow Transplant Date: 2020-04-20 Impact factor: 5.742
Authors: Nilanjan Ghosh; Xiaobu Ye; Hua-Ling Tsai; Javier Bolaños-Meade; Ephraim J Fuchs; Leo Luznik; Lode J Swinnen; Douglas E Gladstone; Richard F Ambinder; Ravi Varadhan; Satish Shanbhag; Robert A Brodsky; Ivan M Borrello; Richard J Jones; William Matsui; Carol Ann Huff Journal: Biol Blood Marrow Transplant Date: 2017-07-12 Impact factor: 5.742
Authors: S El Mahou; M Attal; B Jamard; A Constantin; A Cantagrel; B Mazières; C Arnaud; M Laroche Journal: Clin Rheumatol Date: 2005-11-23 Impact factor: 2.980
Authors: S Iacobelli; L C de Wreede; S Schönland; B Björkstrand; U Hegenbart; A Gruber; H Greinix; L Volin; F Narni; A M Carella; M Beksac; A Bosi; G Milone; P Corradini; K Friberg; A van Biezen; H Goldschmidt; T de Witte; C Morris; D Niederwieser; L Garderet; N Kröger; G Gahrton Journal: Bone Marrow Transplant Date: 2015-01-26 Impact factor: 5.483